Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

TDR Insider

Lab Stakeholders Take Action to Prevent Drastic Cuts in the Medicare Lab Fee Schedule

TDR Insider / By Mary Van Doren

WITH MANY CLINICAL LABORATORY STAKEHOLDERS anticipating major revenue shortfalls due to the Protecting Access to Medicare Act lab test market price reporting rule that went into effect January 1, THE DARK REPORT reports overlooked news that, at the behest of clinical laboratory associations, elected officials in Congress have signed a letter that asks the Centers for Medicare & Medicaid Services to …

Lab Stakeholders Take Action to Prevent Drastic Cuts in the Medicare Lab Fee Schedule Read More »

To access this post, you must purchase The Dark Report.

Cleveland Clinic and related lab sue True Health Diagnostics

TDR Insider / By Mary Van Doren

THE DARK REPORT is the only lab industry news source to recognize the significance of the lawsuit between the Cleveland Clinic Foundation and Cleveland HeartLab against a new lab company, True Health Diagnostics. It is the latest chapter in a string of questionable sales practices engaged in by defendants in the federal whistleblower lawsuit against Health …

Cleveland Clinic and related lab sue True Health Diagnostics Read More »

To access this post, you must purchase The Dark Report.

Might Lawsuits Come Next in the Theranos Story?

TDR Insider / By Mary Van Doren

Tailored to the needs and interests of lab administrators and pathologists, THE DARK REPORT provides new insights into the continuing saga of Theranos. A stream of headline stories in recent weeks has painted the controversial lab testing company in an uncomplimentary way, and TDR puts you front and center in these important developments. Have you been …

Might Lawsuits Come Next in the Theranos Story? Read More »

To access this post, you must purchase The Dark Report.

Lab Professionals Long Knew of Challenges at Theranos

TDR Insider / By Mary Van Doren

CEO SUMMARY: As THE DARK REPORT has continually reported, pathologists and medical laboratory professionals in the San Francisco and Phoenix markets were aware for most of the past year that Theranos was not delivering to patients and consumers the specific lab testing services it regularly touted in news stories and at conferences. Another sign was that, …

Lab Professionals Long Knew of Challenges at Theranos Read More »

To access this post, you must purchase The Dark Report.

Protecting Access to Medicare Act of 2014: Will price reporting rule drive small labs out of business?

TDR Insider / By Mary Van Doren

This first assessment of the PAMA (Protecting Access to Medicare Act of 2014) proposed rule on market reporting of lab prices gives pathologists and lab executives insights about the good, the bad, and the ugly in the language of the proposed rule. One lab group representing independent and community lab companies says that the proposed …

Protecting Access to Medicare Act of 2014: Will price reporting rule drive small labs out of business? Read More »

To access this post, you must purchase The Dark Report.

New Developments in $1 Billion Laboratory Fraud Case

TDR Insider / By Mary Van Doren

IT’S THE $1 BILLION LABORATORY FRAUD that no one realized had grown so big. In this special issue of THE DARK REPORT, you’ll read how the next chapter of the federal whistleblower lawsuit against three specialty cardiology labs and certain individuals has pulled the curtain open on what we believe is the biggest case of laboratory fraud and abuse in the past 30 years. Court documents …

New Developments in $1 Billion Laboratory Fraud Case Read More »

To access this post, you must purchase The Dark Report.

Is New Cycle of Laboratory Fraud Plaguing the Industry?

TDR Insider / By Mary Van Doren

CEO SUMMARY: Taken collectively, the growing number of federal investigations of lab companies and health insurer lawsuits against lab companies alleging fraudulent business practices signals a disturbing new trend for the lab industry. In THE DARK REPORT’s typical hard-hitting analysis of an emerging clinical laboratory trend, it is noted that while these allegations are leveled at just a handful of …

Is New Cycle of Laboratory Fraud Plaguing the Industry? Read More »

To access this post, you must purchase The Dark Report.

New company ready to heat up slow digital pathology market

TDR Insider / By Mary Van Doren

IN THE 2000S, DIGITAL PATHOLOGY WAS THE HOT NEW TECHNOLOGY that held great potential to transform anatomic pathology in myriad ways, not the least of which was an essential tool to streamline pathologist workflow while supporting greater diagnostic precision. Yet today, approximately 10 years later, those high hopes for the digital pathology market have not …

New company ready to heat up slow digital pathology market Read More »

To access this post, you must purchase The Dark Report.

Combining Lean Techniques with Lab Automation to Get Impressive Results

TDR Insider / By Mary Van Doren

PROBABLY NO AREA OF CLINICAL LABORATORY MEDICINE is experiencing the dramatic transformation happening in microbiology. From rapid molecular testing to the full automation of traditional manual processes, significant changes are happening in microbiology labs. Moreover, the smart use of Lean techniques and quality management techniques magnify the positive effects of these new diagnostic technologies and …

Combining Lean Techniques with Lab Automation to Get Impressive Results Read More »

To access this post, you must purchase The Dark Report.

Medicare Ends Coverage for Some Pharmacogenomic Testing

TDR Insider / By Mary Van Doren

CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain, depression, anxiety, and cancer. Meanwhile, medical centers such as Mayo Clinic are conducting clinical studies to collect evidence that appropriate use of pharmacogenomic tests can improve patient outcomes while also reducing the cost of care.

To access this post, you must purchase The Dark Report.

;